- Cancer Drugs
- Diabetes Drugs
- Mental Illness Drugs
- Cardiovascular Disease Drugs
- Hypertension Drugs
- Inflammation Drugs
- Allergy Drugs
- Central Nervous System Drugs
- Neurology Drugs
- Asthma Drugs
- Hepatitis Drugs
- Arthritis Drugs
- Osteoporosis Drugs
- Tuberculosis Drugs
- Malaria Drugs
- Alzheimer Drugs
- Parkinson Disease Drugs
- HIV
- Multiple Sclerosis Drugs
- Autoimmune Drugs
- Insomnia Drugs
- Obesity Drugs
- Gaucher Drugs
- Anemia Drugs
- Crohn Drugs
- Huntington Drugs
- Paget Drugs
Diseases & treatment Market Research Reports
Title | published | price | |
---|---|---|---|
Multiple Sclerosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateBy Global Markets Direct "...... of the Multiple Sclerosis (Central Nervous System) pipeline landscape.
Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to......" | 30-Nov-2022 | $2500 | |
Canavan Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateBy Global Markets Direct "...... e Canavan Disease (Central Nervous System) pipeline landscape.
Canavan disease is a gene-linked neurological disorder in which the brain degenerates into spongy tissue riddled with microscopic fluid-filled spaces. Cause includes a mutati......" | 30-Nov-2022 | $2000 | |
Globoid Cell Leukodystrophy (Krabbe Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateBy Global Markets Direct "...... ) - Drugs In Development, 2022, provides an overview of the Globoid Cell Leukodystrophy (Krabbe Disease) (Central Nervous System) pipeline landscape.
Krabbe disease also called globoid cell leukodystrophy is a degenerative disorder cause......" | 30-Nov-2022 | $2000 | |
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateBy Global Markets Direct "...... of the Huntington Disease (Central Nervous System) pipeline landscape.
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. HD is a familial disease that is passed on from parent ......" | 30-Nov-2022 | $2500 | |
Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateBy Global Markets Direct "...... le System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Drugs In Development, 2022, provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline ......" | 30-Nov-2022 | $2000 | |
Progressive Supranuclear Palsy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateBy Global Markets Direct "...... 22, provides an overview of the Progressive Supranuclear Palsy (Central Nervous System) pipeline landscape.
Progressive supranuclear palsy, also called Steele-Richardson-Olszewski syndrome is a rare neurodegenerative disease that leads t......" | 30-Nov-2022 | $2000 | |
Ornithine-Transcarbamylase Deficiency Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateBy Global Markets Direct "...... evelopment, 2022, provides an overview of the Ornithine-Transcarbamylase Deficiency (Genetic Disorders) pipeline landscape.
Ornithine transcarbamylase (OTC) deficiency is a rare X-linked genetic disorder characterized by complete or part......" | 30-Nov-2022 | $2000 | |
Gaucher Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateBy Global Markets Direct "...... e Gaucher Disease (Genetic Disorders) pipeline landscape.
Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung d......" | 30-Nov-2022 | $2000 | |
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateBy Global Markets Direct "...... r Syndrome ) - Drugs In Development, 2022, provides an overview of the Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) (Genetic Disorders) pipeline landscape.
MPS I (Mucopolysaccharidosis I) is an inherited lysosomal storage disorder ......" | 30-Nov-2022 | $2000 | |
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 UpdateBy Global Markets Direct "...... unter Syndrome ) - Drugs In Development, 2022, provides an overview of the Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) (Genetic Disorders) pipeline landscape.
Mucopolysaccharidosis type II (MPS II), also known as Hunter syndrome......" | 30-Nov-2022 | $2000 | |
|